Percutaneous Trigger Finger Release Concomitant Steroid Injection Versus Percutaneous Trigger Finger Release Alone

Background:

Percutaneous A1 pulley release is a cost-effective and straightforward procedure with outcomes comparable to open A1 pulley release. Postoperative pain is a prevalent concern. Corticosteroid injection is a common nonoperative treatment for trigger finger, providing favorable outcomes but associated with a notable risk of recurrence. Numerous studies have explored the combined approach of percutaneous trigger finger release with corticosteroid injection. However, to date, there is no report on early postoperative results.

Objective:

To conduct a comparative analysis of early postoperative outcomes between percutaneous A1 pulley release with steroid injection and percutaneous A1 pulley release alone.

Study Design & Methods:

This study constitutes a randomized controlled trial involving patients with trigger finger who underwent percutaneous release surgery from October 2023 to January 2024. A total of 38 patients were enrolled, with 18 assigned to the percutaneous A1 pulley release with steroid injection group and 20 to the percutaneous A1 pulley release alone group. Postoperative assessments included pain scores using the Visual Analog Scale (VAS), evaluation of quality of life through the QuickDASH score (qDASH), patient satisfaction, and complications.

Study Overview

• Status: Completed
• Conditions: Postoperative Pain; Trigger Finger; Percutaneous A1 Pulley Release; Steroid Injection
• Intervention / Treatment: Procedure: percutaneous A1 pulley release; Drug: Triamcinolone

Detailed Description

Material and Methods

Study Population:

Patients diagnosed with trigger finger, aged 18 years or older, and classified under Quinell's grade 2, 3, or 4, were included in the study [ ]. Recruitment took place at the Outpatient Orthopedic Department of the Police General Hospital between October 2023 and January 2024. Exclusion criteria encompassed individuals with a history of prior hand surgery, Dupuytren's disease, type 1 diabetes, previous phalangeal fractures, recent steroid injection within the last month, and autoimmune diseases.

Group allocation and Randomization:

Patients were enrolled and randomized into two groups, percutaneous A1 pulley release with steroid injection (Group A) and percutaneous A1 pulley release alone (Group B), by utilizing computer generate randomization and the results were put in opaque sealed envelopes. Informed consent was obtained from all participants, and surgeries were performed by the same surgeon (WJ).

Surgical Technique:

The surgical procedure followed Eastwood's method [ ], involving the following steps:

1. Preparation of the sterile field.
2. Injection of 1% lidocaine with epinephrine at the surgical site.
3. Insertion of an 18-gauge needle following the tract from the previous injection.
4. Patient extension of the finger to bring flexor tendons close to the skin, moving the neurovascular structures away.
5. Slow penetration of the needle until it is over the A1 pulley.
6. Gentle flexion of the finger while observing the needle tip to prevent penetrating the flexor tendon.
7. Rotation of the needle bevel into a longitudinal orientation to the flexor tendon.
8. Release of the A1 pulley by moving the needle upward and downward parallel to the flexor tendon until complete release is achieved.
9. Withdrawal of the needle while hyperextending the finger.
10. Flexion and extension of the finger to check for triggering.
11. Injection of triamcinolone (40mg/ml) 1 ml in the study group.
12. Closure of the wound with a small elastic dressing.

Postoperative Protocols:

Both groups received identical postoperative protocols, including the same medications (Augmentin, Naproxen, Tolperisone) for 7 days. Patients were encouraged for early finger range of motion without restriction.

Outcome Measures:

The primary outcome measure was pain score assessed by the VAS. Secondary outcomes included quality of life measured by the qDASH score, patient satisfaction, and surgical complications.

Follow-Up:

All cases underwent follow-up via telephone on postoperative days 1 to 6, in the clinic during the first and second weeks, and at 1 to 2 months postoperative.

Statistical analysis In this study, all data calculations were conducted using Stata software (version 17.0). Group comparisons involved the application of Pearson's chi-squared test or Continuity Correction chi-squared test for categorical variables, and the student's t-test was employed for continuous variables. Statistically significant differences were defined as those with a P-value < 0.05.

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Phase 3

Contacts and Locations

Study Locations

• Thailand
  • Pathumwan
    • Bangkok, Pathumwan, Thailand, 10330
      • Police General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• clinical diagnosis of trigger finger
• aged 18 years or older
• trigger finger are classified under Quinell's grade 2, 3, or 4

Exclusion Criteria:

• a history of prior hand surgery
• Dupuytren's disease
• type 1 diabetes
• previous phalangeal fractures
• recent steroid injection within the last month
• autoimmune diseases

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: group0; percutaneous A1 pulley release alone	Procedure: percutaneous A1 pulley release; Treatment trigger finger by release A1 pulley by percutaneous procedure
Experimental: group1; percutaneous A1 pulley release with Triamcinolone injection	Procedure: percutaneous A1 pulley release; Treatment trigger finger by release A1 pulley by percutaneous procedure; Drug: Triamcinolone; Triamcinolone 40mg/ml 1 ml injection concomitant percutaneous A1 pulley release

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
postoperative pain score	VAS(visual analog scale) from 0 to 10, 0 mean there is no pain, 10 there is the most pain in participants life	post operative Day0 until 2 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
hand function by quickDASH	quickDASH(questionnaire in Thai version), score from 0-100, 0 mean there is no limitation of daily hand activity, 100 mean participants got disability in that upper limb	post operative Day0 until 2 months
patients satisfaction	1 is lowest satisfaction, 5 is most satisfaction	post operative Day0 until 2 months

Collaborators and Investigators

• Sponsor: Police General Hospital, Thailand

Study record dates

Study Major Dates

• Study Start (Actual): October 11, 2023
• Primary Completion (Actual): January 23, 2024
• Study Completion (Actual): January 30, 2024

Study Registration Dates

• First Submitted: February 17, 2024
• First Submitted That Met QC Criteria: February 23, 2024
• First Posted (Actual): March 1, 2024

Study Record Updates

• Last Update Posted (Actual): March 12, 2024
• Last Update Submitted That Met QC Criteria: March 9, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Muscular Diseases; Tendinopathy; Tendon Entrapment; Trigger Finger Disorder; Physiological Effects of Drugs; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Triamcinolone
• Other Study ID Numbers: 73/256 (Other Identifier: Police General Hospital)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Sharing the Dermographic data of the participants including age, BMI, Occupation and sharing of pain score, quality of life and satisfaction in result table
• IPD Sharing Time Frame: This may be from April 2024 until April 2029
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No